Parallel Health World News Logo

Parallel Health World

cropper
  • Home
  • Categories
    • EcoHealth Trends
    • Healing Naturally
    • Age-Defying Diets
    • Supplement Savvy
    • Mind-Body Synergy
    • Finance and Health
    • Biolimitless
    • Tech Hacks
    • Health & Medicine
    • Political
    • BioBuzz
    • Holistic Rehabilitation Techniques
    • Practitioner Insights
    • AI In Healthcare
  • Featured Business Profiles
October 21.2026
3 Minutes Read

How Scott Hyman's Nuclear Industry Expertise Boosts LIS Technologies' Innovations

Innovative nuclear power plant showcasing futuristic technology.

The Growing Importance of Leadership in the Nuclear Industry

The nuclear industry is at a pivotal moment, with increasing demand for clean energy solutions amidst climate change concerns. Scott Hyman’s addition to LIS Technologies Inc. exemplifies the crucial role experienced leadership plays in steering corporations towards innovation and sustainable practices. With nearly four decades in the industry, Hyman's expertise could significantly influence the trajectory of LIS Technologies as they push forward with their cutting-edge laser uranium enrichment technologies. His leadership is particularly valuable in a landscape that is continually evolving in response to technological advancements and regulatory changes.

Understanding Laser Uranium Enrichment Technology

Laser uranium enrichment represents a significant advancement in nuclear fuel technology, offering a potentially more efficient and cost-effective method of producing enriched uranium. This process minimizes waste and enhances the sustainability of nuclear fuel production. Through the use of advanced laser techniques, LIS Technologies aims to revolutionize how uranium is enriched, ultimately providing cleaner energy solutions. By leveraging his extensive network and knowledge of regulatory environments, Hyman will be instrumental in advocating for the adoption of this innovative technology within the market. His past experiences in strategic marketing and business development will aid in communicating the benefits of this technology to potential clients and partners.

The Future of Nuclear Energy: Opportunities and Challenges

As energy needs evolve, the future of nuclear energy remains ripe with opportunities. The shift towards greener solutions has positioned nuclear power as a significant player in the global energy mix. Moreover, with governments and private sectors investing more in clean energy, nuclear technologies, including those developed by LIS, are expected to receive increased attention and funding. Hyman's expertise will help LIS navigate the various challenges that accompany this industry's growth, including public perception, regulatory compliance, and technological hurdles. Overcoming skepticism about nuclear power and ensuring public safety will be crucial to expanding its role in achieving global energy goals.

Why Does This Matter to Investors and Stakeholders?

The appointment of Scott Hyman is not just another corporate shift; it signals to investors and stakeholders that LIS Technologies is serious about harnessing advanced technologies for a sustainable future. As companies like LIS move toward innovative energy solutions, awareness of market shifts becomes essential for investment strategies. Investors should keep a close watch on how leadership decisions impact the company’s direction and market opportunities. From a financial standpoint, advancements in technology often lead to increased efficiencies and, potentially, improved profit margins, making this a compelling time for investors to consider their positions within the nuclear sector.

Local to Global: The Impact of Nuclear Energy Innovations

Hyman’s role at LIST potentially affects more than just the company; it represents a shift in how the U.S. positions itself in the global energy landscape. With countries worldwide striving for carbon neutrality and sustainable energy solutions, innovations initiated at a local level can ripple out, affecting international energy policies. As nations work towards achieving their climate goals, advancements in the nuclear industry—especially those driven by experienced leaders like Hyman—could reshape global energy discussions. The rise of laser uranium enrichment technologies could serve as a model for more efficient energy production methods worldwide, potentially influencing international standards and practices.

Conclusion: The Path Forward for LIS Technologies

The inclusion of Scott Hyman as Director of Nuclear Fuels Marketing at LIS Technologies is a strategic move aimed at positioning the company at the forefront of an evolving market. His wealth of experience and expertise in the nuclear field can provide critical guidance as LIST explores its laser enrichment technologies. As the industry continues to transform, the insights Hyman brings could lead to significant innovations that help redefine nuclear power's role in a sustainable energy future. Stakeholders and the general public should remain informed about how such leadership changes can influence the broader energy dialogue and contribute to sustainable energy solutions. It's a pivotal time for LIS Technologies as they harness both technological advancement and seasoned leadership to carve out their niche in the market.

Tech Hacks

0 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
10.15.2026

How Avatar Medical's CE Marking Shapes the Future of 3D Medical Imaging

Update Revolutionizing Medical Imaging: The First CE-Marked Glasses-Free 3D Software In a significant milestone for the field of medical imaging, Avatar Medical has announced that its innovative Avatar Medical Vision software has received CE marking, making it the first software approved for use with a glasses-free 3D medical display. This cutting-edge development was highlighted during the Journées Francophones de Radiologie (JFR 2026) in Paris and marks a pivotal step in enhancing surgical planning and patient consultations across Europe. This achievement not only demonstrates Avatar Medical's commitment to improving healthcare technology but also emphasizes the increasing importance of advanced imaging techniques in modern medicine. Why Glasses-Free Technology Matters in Healthcare Traditionally, 3D imaging in medical settings required headsets that can be cumbersome and sometimes unreliable. By eliminating the need for headgear, Avatar Medical Vision allows surgeons and patients to experience depth perception similar to that provided by headsets, but in a more accessible format. This significant transition to glasses-free technology offers numerous benefits, such as reducing the clutter associated with headsets and cables and promoting a seamless workflow in busy clinical environments. Moreover, it minimizes the maintenance and logistical challenges often involved in managing headset-based systems, making it a more practical solution for everyday use in hospitals and clinics. Transforming Surgical Planning and Patient Communication Avatar Medical Vision is designed not only for surgeons but also for enhancing patient understanding during consultations. The software transforms CT and MRI scans into lifelike 3D visualizations, making complex anatomy more comprehensible for patients. This capability is crucial in building trust and facilitating better conversations between doctors and patients regarding treatment options. With improved visualization, patients can engage more actively in their healthcare decisions, asking informed questions about their procedures and outcomes. This empowerment may contribute to patient satisfaction and adherence to treatment plans, reflecting the overall aim of fostering a collaborative healthcare environment. Building a Stronger International Presence This new CE marking builds on Avatar Medical's prior achievements, including its initial CE marking in 2025, and paves the way for wider international growth. With regulatory clearances in both Europe and the United States, Avatar Medical stands poised to drive broader adoption of its glasses-free 3D technology across two vital healthcare markets. As healthcare systems increasingly seek to integrate innovative technologies, Avatar Medical's solutions may play a pivotal role in enhancing clinical outcomes and operational efficiency. Future of Visual Intelligence in Surgery Avatar Medical is spearheading a movement towards what they term "Visual Intelligence for Surgery." This concept encompasses the entire surgical care continuum, from initial patient consultations through to surgical interventions. By making patient-specific imagery readily accessible, the company aims to enhance decision-making processes, ultimately leading to improved surgical outcomes. This shift towards more intuitive visualization tools reflects a growing recognition of the importance of personalized medicine, where visual insights can guide tailored treatment approaches for individual patients. The Bigger Picture: Adapting to Changing Healthcare Needs The advancements in 3D visualization technology reflect a broader trend towards personalized medicine, where detailed imaging helps tailor surgical approaches to individual patients' needs. According to recent studies, enhanced visualization tools like those offered by Avatar Medical can significantly reduce surgical risks and increase the efficiency of medical procedures, allowing for safer and more effective patient care. As the healthcare landscape continues to evolve, healthcare providers will need to adapt to these innovations to meet growing patient expectations and improve outcomes. Common Misconceptions About 3D Medical Imaging Despite the clear benefits of glasses-free 3D imaging, misconceptions persist in the healthcare community. Some may argue that such technologies are not necessary or may complicate existing workflows. However, evidence suggests that integrating these advanced tools can streamline processes and ultimately save time and resources in the operating room and beyond. Additionally, as more healthcare providers witness the advantages of 3D visualization, the industry may see a shift in perception regarding the necessity and impact of adopting such technologies. Conclusion: A Step Towards Enhanced Patient Care Avatar Medical Vision's receipt of CE marking is not just a regulatory achievement—it represents a transformative shift in medical imaging and surgical planning. By making complex anatomical visuals easier for both clinicians and patients to understand, this technology could redefine the surgical journey and significantly impact outcomes in patient care. The progress demonstrated by Avatar Medical also underscores the broader implications of technological advancements in healthcare, emphasizing the need for ongoing innovation and adaptation to meet the demands of modern medicine.

09.29.2026

TempraMed's Upsized Offering: A Smart Investment for Future Growth

Update TempraMed Upsizes Its Offering: What This Means for InvestorsIn a strategic move, TempraMed Technologies Ltd. recently announced an upsized non-brokered private placement, aiming to raise up to C$1.6 million through the sale of convertible debentures and units. This initiative, which modifies a previous offering, highlights the company's growth aspirations in the rapidly evolving healthcare technology market. At a time when healthcare technology is increasingly becoming central to patient management and treatment, TempraMed's decision to expand its offering illustrates a robust response to market demands.Understanding the Upsized OfferingThe upsized offering comprises two key components: up to C$600,000 in unsecured convertible debentures and C$1,000,000 in units. Each unit consists of one common share and a share purchase warrant, allowing investors to acquire additional shares at a price of C$1.00 within 18 months. This structured approach not only provides immediate capital but also incentivizes investors with the potential for future gains as the company grows. This kind of financing is particularly appealing to investors interested in the innovative healthcare sector, providing an opportunity to engage with a company dedicated to improving patient outcomes.Why the Funds Matter: Priorities and Future GoalsTempraMed plans to utilize the proceeds from this offering to enhance its product initiatives and expand its global sales and marketing capabilities. By focusing on new inventory and product development, the company aims to reinforce its position in the medical device sector, specifically in temperature-controlled medication storage solutions. This strategy aligns with the increasing demand for reliable health technologies that ensure medication efficacy. With the healthcare landscape rapidly changing, focusing on innovative solutions to preserve medication integrity is critical for providers and patients alike.The Significance of Temperature-Controlled SolutionsThe importance of preserving medication efficacy through temperature control cannot be overstated. Products like TempraMed's VIVI Cap™ and VIVI Epi™ are designed for seamless medication management without requiring external power sources. These innovations not only contribute to better patient care but also meet critical regulatory standards in various countries. As healthcare continues to innovate, TempraMed's solutions address a crucial element of patient care, showcasing the company’s commitment to safeguarding medications. These temperature-controlled solutions can significantly reduce medication waste, helping healthcare systems save costs while ensuring patients receive the medications they need.The Global Expansion of TempraMedWith operations currently spanning North America, Europe, and Asia, the company is poised to capitalize on its increasing reputation for excellence in medical solutions. TempraMed's ability to navigate the complexities of a global market is essential as it tailors its offerings to meet diverse healthcare needs and regulatory environments. The funds acquired from this upsized offering will further fuel its ability to adapt, allowing for expansion into emerging markets where the demand for reliable healthcare solutions is on the rise. As the global population grows and ages, the necessity for effective medication management will only increase, positioning TempraMed favorably for sustained growth.Investor ConsiderationsInvestors should consider the implications of the upsized offering as an indication of TempraMed’s confidence in its growth trajectory. The combination of convertible debentures and shares presents a flexible investment opportunity, with potential upside depending on the company’s performance. However, as with any investment in emerging healthcare technologies, investors should remain aware of risks, including market competition and regulatory challenges. The healthcare market is notorious for its potential volatility, and while TempraMed's offerings address a critical need, potential investors must conduct their due diligence before committing to investments.Final Thoughts: The Future of TempraMedTempraMed’s upsized offering reflects its commitment to innovation and provides an opportunity for investors to participate in a growing segment of the medical industry. By investing in technology that ensures the efficacy of lifesaving treatments, stakeholders can play a role in the future of healthcare technology. The company’s proactive approach in scaling its operations positions it well in the face of global healthcare challenges. With a mission to safeguard the effectiveness of life-saving medications, TempraMed is not just looking to profit but to make a meaningful impact on patient care worldwide. This investment in their future could lead to stronger healthcare systems globally, influencing how medications are managed in challenging environments. In conclusion, as TempraMed advances, it does not merely expand its portfolio; it paves the way for the future of medication management in healthcare.

09.26.2026

Cheelcare's First Quarter Results Show Remarkable Growth and Innovation in Mobility Solutions

Update Unlocking Potential: Cheelcare's Strong Q1 Performance and Future AmbitionsOn September 25, 2026, Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF), a trailblazer in advanced mobility solutions, unveiled its financial results for the first quarter of fiscal 2027. The results highlight a robust trajectory for the company, showcasing significant growth following the introduction of its Companion power-assist technology to the U.S. market. With revenues reaching $828,516, a staggering 98% increase compared to the same period last year, it is evident that the strategic push for reimbursement access is starting to pay off.A Strategic Leap Forward in CommercializationOne of the key operational milestones reported by Cheelcare is the advancement of Companion's commercialization in the U.S. market. Since obtaining Medicare and Medicaid reimbursement eligibility in January 2026, there has been notable engagement across dealer, clinician, and funding networks. This enables Cheelcare to expand its market footprint efficiently, and as CEO Eugene Cherny remarked, adapting to reimbursement access will be crucial for sustained growth. The importance of aligned regulatory landscapes in both Canada and the U.S. cannot be overstated as they play a pivotal role in the adoption of innovative technologies that empower users.Innovation Recognized: Patent Milestones and Technological EdgeDuring this quarter, Cheelcare also received significant recognition for its technological innovations. A Canadian patent was issued for the Companion platform, safeguarding its core technologies. This advancement not only fortifies Cheelcare's competitive positioning in North America but also enhances investor confidence as intellectual property serves as a vital asset for future growth. As more companies enter the mobility sector, securing patents can significantly bolster a company's standing by ensuring uniqueness in their offerings.Addresses Market Requirements: Moving Forward with CurioAlongside Companion, Cheelcare has continued to invest in its Curio robotic power wheelchair, which remains essential to the company’s vision of delivering advanced mobility solutions. By participating in the Numotion Commercial Growth Summit, Cheelcare's leadership was able to directly engage with significant stakeholders in the rehabilitation technology space. This indicates a proactive approach to not just innovation, but also to establishing partnerships that can enhance product reach and visibility.Financial Health: A Closer LookWhile revenues have soared, the company reported a net loss of $501,008, a noticeable improvement from the previous year when it recorded a loss of $1,630,108. The reduction in loss can largely be attributed to the company's successful fundraising efforts, including a recent $3.02 million private placement that bolstered its cash reserves to $2.4 million. These funds will assist in continuing product development and commercialization of its unique technologies, positioning Cheelcare for potential profitability as market acceptance grows.Broader Context: The Growing Need for Mobility InnovationsThe growing emphasis on mobility solutions is reflective of broader healthcare trends that aim to enhance the quality of life for individuals with disabilities. As society increasingly recognizes the importance of independence and quality of life, companies like Cheelcare stand to play an integral role in facilitating these needs. The evolution of regulations and market access in this sector suggests opportunity for significant growth, not just for Cheelcare but for all innovators seeking to contribute positively to healthcare mobility.The Road Ahead: Vision for Sustainable GrowthMoving forward, Cheelcare's objectives will likely center on transforming increased distribution capabilities into tangible sales growth. Additionally, improvements in manufacturing efficiency, coupled with further advancements in technology, will likely enhance the operational logistics for Companion and Curio. As technology continues to evolve, Cheelcare’s commitment to innovation will be a key driver for future success. The combination of strategic partnerships and technological advancements can potentially change the landscape of mobility solutions.Cheelcare's dedication to developing cutting-edge mobility aids is more than a business strategy; it represents a mission to redefine the mobility experience for those who rely on these essential devices. As the company navigates through its expansion journey, stakeholders eagerly await the anticipated outcomes of its strategic initiatives and the impact they will have on the industry.

Where Conventional Meets Natural for a Healthier You

Parallel Health World News offers clarity and actionable knowledge for those eager to harmonize the best of both medical worlds, helping its audience achieve a truly integrative approach to health and wellness.

Advertise
Parallel Health World News
SeamanDan.com
Dan Seaman Media Press Pass

ABOUT US
SeamanDan LLC is a modern news media agency creating niche digital channels that inform and engage. We specialize in launching focused platforms that deliver impactful content.  Our current brands include:
Parallel Health World
AI Insights Hub
MLM News AI
Rider Safe News
Meme Crypto News
Rugged Trails Network
Recreation Wave
Outdoor Odyssey News
Eco-Innovation Hub
Metal Green Innovators
Autism Foundation News

At SeamanDan LLC, we don't just report the news we create platforms that build communities, foster trust, and drive forward-thinking conversations.  Can we build a channel for you?

© 2026 Parallel Health World News All Rights Reserved. 810 N Main St #187, Spearfish, SD 57783 . Contact Us . Terms of Service . Privacy Policy

{"company":"Parallel Health World News","address":", ,  ","city":"","state":"","zip":"","email":"seamandan@seamandan.com","tos":"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","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*